A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
Recruiting
Peloton Therapeutics, Inc.
Phase 2
2018-09-27
This is an open-label Phase 2 study which will evaluate the efficacy and safety of belzutifan
in combination with cabozantinib in participants with advanced ccRCC. Belzutifan and
cabozantinib will be administered orally once daily.
A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)
Not yet recruiting
Merck Sharp & Dohme Corp.
Phase 1
2021-12-06
The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of
belzutifan (MK-6482) following a single oral 120 mg dose in participants with end stage renal
disease (ESRD) before and after hemodialysis (HD) to each other and also to that of healthy
matched control participants. This study will also evaluate the safety and tolerability of a
single oral 120 mg dose of belzutifan in participants with ESRD and the extent of belzutifan
removed by HD.
Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020)
Not yet recruiting
Merck Sharp & Dohme Corp.
Phase 1
2021-12-06
The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of
belzutifan (MK-6482) following a single oral 120 mg dose of belzutifan in participants with
moderate hepatic impairment to that of healthy matched control participants. This study will
also evaluate the safety and tolerability of a single oral 120 mg dose of belzutifan in
participants with moderate hepatic impairment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
